Hims & Hers Health, Inc. (NYSE:HIMS) will release its second quarter earnings report after the closing bell on Monday, Aug. 10.
Analysts expect the San Francisco, California-based company to report a quarterly loss of 5 cents per share, versus earnings of 17 cents per share in the year-ago period. The consensus estimate for Hims & Hers Health’s quarterly revenue is $730.12 million. It reported $544.83 million last year, according to Benzinga Pro.
On July 23, an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list.
Hims & Hers Health shares gained 6.5% to close at $31.59 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- B of A Securities analyst Allen Lutz maintained a Neutral rating and raised the price target from $36 to $37 on July 9, 2026. This analyst has an accuracy rate of 56%.
- Canaccord Genuity analyst Maria Ripps maintained a Buy rating and boosted the price target from $32 to $40 on July 1, 2026. This analyst has an accuracy rate of 69%.
- Barclays analyst Glen Santangelo maintained an Overweight rating and boosted the price target from $29 to $39 on June 18, 2026. This analyst has an accuracy rate of 56%.
- JP Morgan analyst Cory Carpenter maintained an Overweight rating and cut the price target from $35 to $33 on May 12, 2026. This analyst has an accuracy rate of 53%.
- BTIG analyst David Larsen maintained a Neutral rating on May 12, 2026. This analyst has an accuracy rate of 58%.
Considering buying HIMS stock? Here’s what analysts think:
Photo via Shutterstock